The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex

Sulbactam-durlobactam is a beta-lactam/beta-lactamase inhibitor combination currently in development for the treatment of infections caused by Acinetobacter, including multidrug-resistant (MDR) isolates. Although sulbactam is a beta-lactamase inhibitor of a subset of Ambler class A enzymes, it also demonstrates intrinsic antibacterial activity against a limited number of bacterial species, including Acinetobacter, and has been used effectively in the treatment of susceptible Acinetobacter-associated infections. Increasing prevalence of beta-lactamase-mediated resistance, however, has eroded the effectiveness of sulbactam in the treatment of this pathogen. Durlobactam is a rationally designed beta-lactamase inhibitor within the diazabicyclooctane (DBO) class. The compound demonstrates a broad spectrum of inhibition of serine beta-lactamase activity with particularly potent activity against class D enzymes, an attribute which differentiates it from other DBO inhibitors. When combined with sulbactam, durlobactam effectively restores the susceptibility of resistant isolates through beta-lactamase inhibition. The present review describes the pharmacokinetic/pharmacodynamic (PK/PD) relationship associated with the activity of sulbactam and durlobactam established in nonclinical infection models with MDR Acinetobacter baumannii isolates. This information aids in the determination of PK/PD targets for efficacy, which can be used to forecast efficacious dose regimens of the combination in humans.

Automated summary

Sulbactam-durlobactam is a combination of beta-lactam and beta-lactamase inhibitor that is being developed for the treatment of Acinetobacter infections, including multidrug-resistant strains. Sulbactam has intrinsic antibacterial activity against Acinetobacter, but its effectiveness has been reduced by increasing beta-lactamase-mediated resistance. Durlobactam, a rationally designed beta-lactamase inhibitor, effectively restores susceptibility to resistant isolates when combined with sulbactam. This review discusses the pharmacokinetic/pharmacodynamic relationship of the combination in nonclinical infection models and aids in determining effective dose regimens for humans.